BCYC Stock Overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Bicycle Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.67 |
| 52 Week High | US$28.91 |
| 52 Week Low | US$12.54 |
| Beta | 0.89 |
| 1 Month Change | -10.85% |
| 3 Month Change | 27.07% |
| 1 Year Change | 13.41% |
| 3 Year Change | -29.44% |
| 5 Year Change | n/a |
| Change since IPO | 88.92% |
Recent News & Updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19
Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Recent updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year
Jan 19Bicycle Therapeutics gives out pipeline update, shares rise
Jan 14What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?
Dec 15Bicycle Therapeutics settles IP dispute with Pepscan
Nov 30Shareholder Returns
| BCYC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 1.0% | 1.2% |
| 1Y | 13.4% | 0.7% | 24.9% |
Return vs Industry: BCYC exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BCYC underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| BCYC volatility | |
|---|---|
| BCYC Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCYC's share price has been volatile over the past 3 months.
Volatility Over Time: BCYC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 284 | Kevin Lee | www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
Bicycle Therapeutics plc Fundamentals Summary
| BCYC fundamental statistics | |
|---|---|
| Market cap | US$967.83m |
| Earnings (TTM) | -US$180.66m |
| Revenue (TTM) | US$26.98m |
35.9x
P/S Ratio-5.4x
P/E RatioIs BCYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCYC income statement (TTM) | |
|---|---|
| Revenue | US$26.98m |
| Cost of Revenue | US$156.50m |
| Gross Profit | -US$129.52m |
| Other Expenses | US$51.14m |
| Earnings | -US$180.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.23 |
| Gross Margin | -480.13% |
| Net Profit Margin | -669.72% |
| Debt/Equity Ratio | 8.3% |
How did BCYC perform over the long term?
See historical performance and comparison